Skip to main content
. 2021 Jan 15;16(1):e0245131. doi: 10.1371/journal.pone.0245131

Table 1. Comorbidities in the full dataset (n = 861).

Condition Full-cohort (n = 861) CKD only (n = 584) No CKD (n = 277)
N % (95% CI) N % (95% CI) N % (95% CI)
CKD 584 67.8 (64.7 to 70.9) 584 100 0 0
Hypertension 512 59.5 (56.2 to 62.7) 374 64.0 (60.1 to 67.9) 138 49.8 (43.9 to 55.7)
Obesity 264 30.7 (27.5 to 33.7) 174 29.8 (26.1 to 33.5) 90 32.5 (27.0 to 38.0)
Ischaemic heart disease 146 17.0 (14.5 to 19.5) 113 19.4 (16.1 to 22.6) 33 11.9 (8.1 to 15.7)
Diabetes 133 15.5 (13.0 to 17.9) 109 18.7 (15.5 to 21.8) 24 8.7 (5.3 to 12.0)
Atrial fibrillation 110 12.8 (10.5 to 15.0) 84 14.4 (11.5 to 17.2) 26 9.4 (6.0 to 12.8)
Thyroid disease 106 12.3 (1.1 to 14.5) 67 11.5 (8.9 to 14.1) 39 14.1 (10.0 to 18.2)
Anaemia 90 10.5 (8.4 to 12.5) 71 12.2 (9.5 to 14.8) 19 6.9 (3.9 to 9.8)
Cerebrovascular disease 73 8.5 (6.6 to 10.3) 59 10.1 (7.7 to 12.5) 14 5.1 (2.5 to 7.6)
Osteoporosis 64 7.4 (5.7 to 9.2) 42 7.2 (5.1 to 9.3) 22 7.9 (4.8 to 11.1)
Osteopenia 45 5.2 (3.7 to 6.7) 34 5.8 (3.9 to 7.7) 11 4.0 (1.7 to 6.3)
TIA 42 4.9 (3.4 to 6.3) 33 5.7 (3.8 to 7.5) 9 3.3 (1.2 to 5.3)
Heart failure 39 4.5 (3.1 to 5.9) 32 5.5 (3.6 to 7.3) 7 2.5 (0.7 to 4.4)
Peripheral vascular disease 29 3.4 (2.2 to 4.6) 18 3.1 (1.7 to 4.5) 11 4.0 (1.7 to 6.3)
Stroke 17 2.0 (1.0 to 2.9) 15 2.6 (1.3 to 3.9) 2 0.7 (0 to 0.2)